{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:24:10Z","timestamp":1787844250872,"version":"build-2784847793"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Systemic juvenile idiopathic arthritis (sJIA) is a diagnosis of exclusion. The complex nature and clinical variety of the disease, as well as the vast clinical variation of disease presentation, may lead to difficulties in disease detection and subsequent delays in treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To provide a consensus guidance on the management of newly diagnosed sJIA patients among pediatric rheumatologists in Arab countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This work was conducted in two phases. The first phase utilized an electronic survey sent through an email invitation to all pediatric rheumatologists in Arab countries. In the second phase, a Task Force of ten expert pediatric rheumatologists from Arab countries met through a series of virtual meetings. Results obtained in phase one were prioritized using a nominal group and Delphi-like techniques in phase two.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seven overarching principles and a set of recommendations were approved by the Task Force to form the final consensus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This is the first consensus on a clinical approach for pediatric rheumatic diseases among Arab pediatric rheumatologists. It is presented as a guidance on the clinical approach to sJIA that requires further evidence, and future updates are anticipated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.ijpam.2021.05.003","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T11:23:33Z","timestamp":1622978613000},"page":"129-133","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Consensus clinical approach for a newly diagnosed systemic juvenile idiopathic arthritis among members of the pediatric rheumatology Arab group"],"prefix":"10.4103","volume":"8","author":[{"given":"Hend M.","family":"Alkwai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Abdwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reima","family":"Bakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullatif","family":"Alenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khulood","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Lotfy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Muzaffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafaa","family":"Al-Suwairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alzyoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman M.","family":"Al-Mayouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20240903","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"R2-1-20240903","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"R3-1-20240903","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.berh.2018.10.004","article-title":"Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis","volume":"32","author":"Palman","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R4-1-20240903","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.pcl.2018.04.005","article-title":"Systemic juvenile idiopathic arthritis","volume":"65","author":"Lee","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"R5-1-20240903","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of Macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter Study of 362 Patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R6-1-20240903","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C","article-title":"Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study","volume":"43","author":"Spiegel","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R7-1-20240903","first-page":"211","article-title":"Systemic onset juvenile chronic arthritis, polyarticular pattern and hip involve- mentas markers for a bad prognosis","volume":"19","author":"Modesto","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"R8-1-20240903","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00296-018-4062-9","article-title":"Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment","volume":"38","author":"Nalbanti","year":"2018","journal-title":"Rheumatol Int"},{"key":"R9-1-20240903","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/BOR.0000000000000620","article-title":"Predicting disease severity and remission in juvenile idiopathic arthritis: are we getting closer?","volume":"31","author":"Guzman","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R10-1-20240903","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00296-019-04478-3","article-title":"Pattern and diagnostic evaluation of systemic autoinflammatory diseases other than familial Mediterranean fever among Arab children: a multicenter study from the Pediatric Rheumatology Arab Group (PRAG)","volume":"40","author":"Al-Mayouf","year":"2020","journal-title":"Rheumatol Int"},{"key":"R11-1-20240903","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0140-6736(98)11185-6","article-title":"Clinical trials, consensus conferences, and clinical practice","volume":"24","author":"Sniderman","year":"1999","journal-title":"Lancet"},{"key":"R12-1-20240903","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/0142159X.2017.1245856","article-title":"Using consensus group methods such as Delphi and Nominal Group in medical education research","volume":"39","author":"Humphrey-Murto","year":"2017","journal-title":"Med Teach"},{"key":"R13-1-20240903","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R14-1-20240903","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"R15-1-20240903","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R16-1-20240903","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R17-1-20240903","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/art.38984","article-title":"Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial","volume":"67","author":"De","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R18-1-20240903","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R19-1-20240903","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.38092","article-title":"2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R20-1-20240903","first-page":"819","article-title":"Treating juvenile idiopathic arthritis to target recommendations of an international Task Force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R21-1-20240903","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","article-title":"Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis","volume":"79","author":"Klein","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R22-1-20240903","doi-asserted-by":"crossref","first-page":"e0170259","DOI":"10.1371\/journal.pone.0170259","article-title":"Systematic review of the toxicity of long- course oral corticosteroids in children","volume":"12","author":"Aljebab","year":"2017","journal-title":"PLoS One"},{"key":"R23-1-20240903","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/rheumatology\/keaa240","article-title":"Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis","volume":"59","author":"Tibaldi","year":"2020","journal-title":"Rheumatology (Oxford"},{"key":"R24-1-20240903","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0022-3476(96)70140-3","article-title":"Macrophage activation syndrome in systemic juvenile rheumatoid arthritis","volume":"129","author":"Grom","year":"1996","journal-title":"J Pediatr"},{"key":"R25-1-20240903","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R26-1-20240903","first-page":"481","article-title":"2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. A European League against rheumatism\/American College of rheumatology\/paediatric rheumatology international trials organisation collaborative initiative","volume":"75","author":"Ravelli","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R27-1-20240903","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2019-215211","article-title":"Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemicjuvenile idiopathic arthritis","volume":"78","author":"Minoia","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R28-1-20240903","first-page":"343","article-title":"Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASO- JAR)","volume":"35","author":"Behrens","year":"2008","journal-title":"J Rheumatol"},{"key":"R29-1-20240903","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.autrev.2007.01.016","article-title":"Ferritin in autoimmune diseases","volume":"6","author":"Zandman-Goddard","year":"2007","journal-title":"Autoimmun Rev"},{"key":"R30-1-20240903","first-page":"431","article-title":"Juvenile chronic arthritis in a Turkish population","volume":"9","author":"Ozdogan","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"R31-1-20240903","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00296-019-04421-6","article-title":"Profile of new referrals to a single pediatric rheumatology center in Turkey","volume":"40","author":"Karada\u011f","year":"2020","journal-title":"Rheumatol Int"},{"key":"R32-1-20240903","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-3476(99)70372-0","article-title":"Malignancies in children who initially present with rheumatic complaints","volume":"134","author":"Cabral","year":"1999","journal-title":"J Pediatr"},{"key":"R33-1-20240903","first-page":"1665","article-title":"Discrimination of acute lymphoblastic leukemia from systemic-onset juvenile idiopathic arthritis at disease onset","volume":"66","author":"Tamashiro","year":"2011","journal-title":"Clinics (Sao Paulo"},{"key":"R34-1-20240903","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R35-1-20240903","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"R36-1-20240903","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/14397595.2020.1783163","article-title":"Efficacy and safety of canakinumab in systemicjuvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients","volume":"31","author":"Nishimura","year":"2021","journal-title":"Mod Rheumatol"},{"key":"R37-1-20240903","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R38-1-20240903","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2011.10.003","article-title":"Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis","volume":"142","author":"Dueckers","year":"2012","journal-title":"Clin Immunol"},{"key":"R39-1-20240903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-018-0224-2","article-title":"PRO-KIND SJIA project collaborators. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany","volume":"16","author":"Hinze","year":"2018","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["International Journal of Pediatrics and Adolescent Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646721000508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352646721000508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijpam.2021.05.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:16:30Z","timestamp":1787843790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.ijpam.2021.05.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijpam.2021.05.003","relation":{},"ISSN":["2352-6467"],"issn-type":[{"value":"2352-6467","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}